Comparing of Myovant Sciences Ltd. (MYOV) and Fortress Biotech Inc. (NASDAQ:FBIOP)

We will be comparing the differences between Myovant Sciences Ltd. (NYSE:MYOV) and Fortress Biotech Inc. (NASDAQ:FBIOP) as far as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences Ltd. 16 0.00 N/A -4.08 0.00
Fortress Biotech Inc. 20 -4.34 N/A -1.38 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Myovant Sciences Ltd. and Fortress Biotech Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Myovant Sciences Ltd. and Fortress Biotech Inc.

Net Margins Return on Equity Return on Assets
Myovant Sciences Ltd. 0.00% -590.4% -157%
Fortress Biotech Inc. 0.00% 0% 0%

Analyst Recommendations

Myovant Sciences Ltd. and Fortress Biotech Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Myovant Sciences Ltd. 0 0 1 3.00
Fortress Biotech Inc. 0 0 0 0.00

The upside potential is 248.19% for Myovant Sciences Ltd. with average target price of $25.

Institutional & Insider Ownership

Institutional investors held 33.4% of Myovant Sciences Ltd. shares and 0% of Fortress Biotech Inc. shares. 56.5% are Myovant Sciences Ltd.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Myovant Sciences Ltd. -9.21% -18.18% -59.09% -61.14% -63.47% -56.12%
Fortress Biotech Inc. 0.06% 1.87% 10.99% 21.61% 2.35% 50.44%

For the past year Myovant Sciences Ltd. had bearish trend while Fortress Biotech Inc. had bullish trend.


Fortress Biotech Inc. beats Myovant Sciences Ltd. on 5 of the 8 factors.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.